Medical Park
Mobile Apps
Medical Oncology
  • Interests
Medical Oncology
  • Interests
İAÜ VM Medical Park Florya (Bakırköy)
Beşyol Mahallesi, Akasya Sk. No: 4 , 34295 Küçükçekmece/İstanbul - İstanbul
444 28 73
İAÜ VM Medical Park Florya (Bakırköy)
Beşyol Mahallesi, Akasya Sk. No: 4 , 34295 Küçükçekmece/İstanbul - İstanbul

Academic Background

Education and Experience
1991-1997 Istanbul University, Cerrahpaşa Faculty of Medicine
1997-2002 Trakya University Faculty of Medicine – Department of Internal Medicine
2002-2004 Trakya University Faculty of Medicine – Medical Oncology
2004-2005 Turkish Air Force Command Etimesgut Military Hospital
2005-2008 Trakya University Faculty of Medicine – Medical Oncology
2008-2010 Elazığ Training and Research Hospital
2010-2015 Trakya University Faculty of Medicine – Associate Professorship
2015 Trakya University Faculty of Medicine – Professorship

Read more

Scientific Publications

 

  1. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. Bilici A, Olmez OF, Kaplan MA, Oksuzoglu B, Sezer A, Karadurmus N, Cubukcu E, Sendur MAN, Aksoy S, Erdem D, Basaran G, Cakar B, Shbair ATM, Arslan C, Sumbul AT, Sezgin Goksu S, Karadag I, Cicin I, Gumus M, Selcukbiricik F, Harputluoglu H, Demirci U. Acta Oncol. 2023 Apr 21:1-10. doi: 10.1080/0284186X.2023.2202330. (April 2023)

 

  1. Major and minor salivary gland cancers: A multicenter retrospective study. Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Biricik FS, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Head Neck. 2023 Apr 21. doi: 10.1002/hed.27376. Online ahead of print. (April 2023)

 

  1. Cancer-related hypercalcemia and potential treatments Elvina Almuradova1 and Irfan Cicin2 Frontiers in Endocrinology. 22 March 2023, DOI 10.3389/fendo.2023.1039490 (March 2023)

 

  1. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz MP, Shimizu C, Huang CS, Lueck HJ, Beith J, Tokunaga E, Contreras JR, de Sant'Ana RO, Wei R, Shahir A, Nabinger SC, Forrester T, Johnston SRD, Harbeck N. Ther Adv Med Oncol. 2023 Feb 3;15:17588359231151840. doi: 10.1177/17588359231151840. eCollection 2023. (February 2023)

 

  1. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Urul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. (February 2023)

 

  1. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Yekedüz E, Karakaya S, Ertürk İ, Tural D, Uçar G, Şentürk Öztaş N, Arıkan R, Hızal M, Küçükarda A, Sever ÖN, Arslan Ç, Can O, Kılıçkap S, Yazgan C, Karadurmuş N, Şendur MA, Çiçin İ, Demirci U, Özgüroğlu M, Öksüzoğlu B, Ürün Y. Clin Genitourin Cancer. 2023 Feb;21(1):175-182. doi: 10.1016/j.clgc.2022.07.006. (February 2023)

 

  1. An experimental study: the effect of S. boulardii on abemaciclibinduced diarrhea. Cakcak İE, Aytın YE, Sayın S, Küçükarda A, Gökyer A, Gökmen İ, Özcan E, Korkmaz S, Taştekin E, Çiçin İ. Turk J Med Sci. 2023 Feb;53(1):51-57. doi: 10.55730/1300-0144.5557. Epub 2023 Feb 22. (January 2023)

 

  1. Abemaciclib plus endocrine therapy for hormone receptorpositive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Stephen R D Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun-Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara M Tolaney, Matthew P Goetz, Hope S Rugo, Elzbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valérie André, Nadia Harbeck, Miguel Martin, on behalf of the monarchE Committee Members* Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694 (January 2023)

 

  1. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study. Gümüş M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477 (January 2023)

 

  1. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Cicin I, Martin C, Haddad CK, Kim SW, Smolin A, Abdillah A, Yang X. Crit Rev Oncol Hematol. 2022 Oct 15:103847. doi: 10.1016/j.critrevonc.2022.103847. (October 2022)

 

  1. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry AndersBjartella, LuisCosta, Gero Kramer, Bogdan Zurawski, LucaGalli, Patrick Werbrouck, Thorsten Ecke, Omi Parikh, Mostefa Bennamoun, Camilo Garcia Freire, Avivit Peer, BörjeLjungberg, IrfanCicin, EmmaSmith, Martin Lukac, Robert Wapenaar, Simon Chowdhury.European Urology Open Science Volume 45, November 2022, Pages 12-22. https://doi.org/10.1016/j.euros.2022.08.018 (September 2022)

 

  1. Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. Cosar R, Sut N, Ozen A, Tastekin E, Topaloglu S, Cicin I, Nurlu D, Ozler T, Demir S, Yıldız G, Şenödeyici E, Uzal MC. Breast Cancer (Dove Med Press). 2022 Sep 8;14:259-280. doi: 10.2147/BCTT.S380754 (September 2022)

 

  1. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Dogan I, Ayhan M, Gurbuz M, Kucukarda A, Aydin E, Urun Y, Cicin I, Saip P. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147. (September 2022)

 

  1. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Özet A, Dane F, Aykan NF, Yalçın Ş, Evrensel T, Özkan M, Karabulut B, Ormeci MN, Atasev O, Vidot L, Çiçin İ. Future Oncol. 2022 Aug 30. doi: 10.2217/fon-2022-0455. (September 2022)

 

  1. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma. Küçükarda A, Gökmen İ, Özcan E, Peker P, Akgül F, Çiçin İ. Immunotherapy. 2022 Feb 14. doi: 10.2217/imt-2021-0275. (February 2022)

 

  1. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinom a: Results from Two Randomized, Open-Label, Phase II Studies Manish A. Shah 1,* ,† , Anghel Adrian Udrea 2 , Igor Bondarenko 3 , Was Mansoor 4, , Raquel Guardeño Sánchez 5 , Tomasz Sarosiek 6, Silvia Bozzarelli 7, Michael Schenker 8,9, Carlos Gomez-Martin 10, Carys Morgan 11,Mustafa Özgüro ˘glu 12 , Joanna Pikiel 13, Haralabos P. Kalofonos 14, Elzbieta Wojcik 15, Tomas Buchler 16, Daniel Swinson 17, Irfan Cicin 18 , Mano Joseph 19, Ihor Vynnychenko 20, Alexander Valerievich Luft 21, Peter C. Enzinger 22, Tomas Salek 23, Christos Papandreou 24, Christophe Tournigand 25, Evaristo Maiello 26 , Ran Wei 27 , David Ferry 28, Ling Gao 28, Joana M. Oliveira 28 and Jaffer A. Ajani 29, Cancers 2022, 14, 1168. https://doi.org/10.3390/cancers14051168 (February 2022)

 

  1. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Shitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, Ozyilkan O, Cicin I, Park D, Zaanan A, Pericay C, Özgüroğlu M, Alsina M, Makris L, Benhadji KA, Ilson DH. Gastric Cancer. 2022 Jan 8. doi: 10.1007/s10120-021-01271-9. (January 2022)

 

  1. Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study Osman Kostek, Ahmet Kucukarda, Hilmi Tozkir, Ilker Nihat Okten, Ercan Ozden, Devrim Cabuk, Murat Sari, Emre Cakir, Ilhan Hacibekiroglu, Mustafa Gurbuz, Yuksel Urun, Bahiddin Yilmaz, Cihan Erol, Mehmet Ali Nahit Sendur, Emrah Eraslan, Umut Demirci, Zeynep Oruc, Mehmet Ali Kaplan, Ali Gokyer, Ivo Gokmen, Erkan Ozcan, Muhammet Bekir Hacioglu, Bulent Erdogan, Selma Demir, Sernaz Uzunoglu, Mahmut Gumus, Hakan Gurkan, Irfan Cicin; JBUON 26 (6) 2654-2661 (December 2021)

 

  1. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib? Bulent Erdogan1, Osman Kostek2, Muhammet Bekir Hacioglu1, Ali Gokyer1, Ahmet Kucukarda, , Erkan Ozcan, , Ivo Gokmen, , Sernaz Uzunoglu , Irfan Cicin. JBUON 2021; 26(5): 2196-2201 (November 2021)

 

  1. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database Emre Yekedüz , İsmail Ertürk, Deniz Tural , Nuri Karadurmuş , Serdar Karakaya , Mutlu Hızal , Rukiye Arıkan, Çağatay Arslan, Hakan Taban, Ahmet Küçükarda , Nihan Şentürk Öztaş, Özlem Nuray Sever , Gökhan Uçar , Orçun Can, Mehmet Ali Nahit Şendur, Umut Demirci , Saadettin Kılıçkap, İrfan Çiçin , Berna Öksüzoğlu , Mustafa Özgüroğlu & Yüksel Ürün See fewer authors Published Online:2 Nov 2021https://doi.org/10.2217/fon-2021-0717 (November 2021)

 

  1. Kelley, R.K., Miksad, R., Cicin, I. et al. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01532-5 (October 2021)

 

  1. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. Topal A, Sayın S, Gokyer A, Kucukarda A, Kostek O, Bekir Hacıoglu M, Uzunoglu S, Erdogan B, Cicin I. J BUON. 2021 Jul-Aug;26(4):1628-1634. (September 2021)

 

  1. Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer. Ay A, Gulyasar T, Alkanli N, Sipahi T, Cicin I, Kocak Z, Sut N. Mol Biol Rep. 2021 Sep 8. doi: 10.1007/s11033-021-06694-2. (September 2021)

 

  1. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. JAMA Oncol. 2021 Sep 2. doi: 10.1001/jamaoncol.2021.3523. (September 2021)

 

  1. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients Ali Alkan1,*, Zeynep Gülsüm Güç2 , Mustafa Gürbüz3, , Güliz Özgün4, Serkan Değirmencioğlu5, , Mutlu Doğan4, , Tuğba Akın Telli6, , Özge Keskin7, , Çağatay Arslan8, , Burak Bilgin9, , Sema Sezgin Göksu10, Hacer Demir11, , Elif Berna Köksoy3, , Osman Köstek12, İsmail Ertürk13, Teoman Şakalar14, Arzu Yaşar15, Görkem Türkkan16, Büşra Kasım17, Aziz Karaoğlu2, , Berna Çakmak Öksüzoğlu4, Fulden Yumuk6, , Mehmet Ali Şendur18, Hasan Şenol Coşkun10, İrfan Çiçin12, Nuri Karadurmuş13, Özgür Tanrıverdi1 ,, Hakan Akbulut3, , Yüksel Ürün3, JOMH, http://www.jomh.org/articles/10.31083/jomh.2021.041 (June 2021)

 

  1. Economic burden of lung cancer in Turkey: a cost of illness study from payer 4 perspective, Irfan Cicin1, Ergun Oksuz2*, Nuri Karadurmus3, Simten Malhan4, , Mahmut Gumus5, , Ulku Yilmaz6, , Levent Cansever7, 6 Halit Cinarka7, , Erdogan Cetinkaya7, Murat Kiyik7, , Ahmet Ozet8, Health Econ Rev . 2021 Jun 26;11(1):22. doi: 10.1186/s13561-021-00322-2. (June 2021)

 

  1. Prognostic Nutritional Index and its Dynamics After Curative Treatment are Independent Prognostic Factors on Survival in Non-Metastatic Nasopharyngeal Carcinoma Küçükarda A, Erdoğan B, Gökyer A, Sayın S, Gökmen İ, Özcan E, Hacıoğlu MB, Uzunoğlu S, Çiçin İ, 04 Jun 2021, DOI: 10.21203/rs.3.rs-429555/v1, Supportive Care in Cancer (June 2021)

 

  1. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-stage Small-cell Lung Cancer Lauren Averett Byers, Alejandro Navarro, Eric Schaefer, Melissa Johnson, Mustafa Özgüroğlu, Ji-Youn Han, Igor Bondarenko, Irfan Cicin, Konstantin H. Dragnev, Adam Abel, Xuejing Wang, Samuel McNeely, Scott Hynes, Aimee Bence Lin, Martin Forster Publication stage: In Press Journal Pre-Proof Clinical Lung Cancer (April 2021)

 

  1. Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey. Özdemir K, Gürkan H, Demir S, Atli E, Özen Y, Sezer A, Tunçbilek N, Çicin I. Balkan J Med Genet. 2021 Mar 23;23(2):49-58. doi: 10.2478/bjmg-2020-0016. eCollection 2020 Nov. (April 2021)

 

  1. Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity. Kucukarda A, Sayın S, Gokyer A, Aykan MB, Karadurmuş N, Cicin İ. Immunotherapy. 2021 Apr 6. doi: 10.2217/imt-2020-0233. (April 2021)

 

  1. Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma. Gökyer A, Küçükarda A, Köstek O, Gökmen İ, Özcan E, Sayın S, Taştekin E, Hacıoğlu B, Erdoğan B, Uzunoğlu S, Çiçin İ. Tumori. 2021 Feb 24:300891621996448. (February 2021)

 

  1. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomized, controlled trial. Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, MustafaÖzgüroğlu, Miranda Gogishvili, Haci M Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Philip Clingan, Virote Sriuranpong, Naiyer Rizvi, Bo Gao, Siyu Li, Sue LeeKristina McGuire, Chieh-I Chen, Tamta Makharadze, Semra Paydas, Marina Nechaeva, Frank Seebach, David M Weinreich, George D Yancopoulos, Giuseppe Gullo, Israel Lowy, Petra Rietschel. Lancet 2021; 397: 592–604 (February 2021)

 

  1. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisam N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA, Xu L, Piperdi B, Samkari A, Reck M; KEYNOTE-598 Investigators. J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579 (February 2021)

 

  1. Clinicopathological and prognostic characteristics of acral metastases in patients with malignant disease: A retrospective study. Çiftdemir M, Ustabaşıoğlu FE, Çölbe SA, Üstün F, Usta U, Çiçin İ. Acta Orthop Traumatol Turc. 2021 Jan;55(1):67-72. doi: 10.5152/j.aott.2020.20052. (January 2021)

 

  1. Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review. Gökyer A, Sayın S, Küçükarda A, Çelik M, Güldiken S, Çiçin İ. Curr Probl Cancer. 2021 Jan 8:100704. doi: 10.1016/j.currproblcancer.2020.100704. (January 2021)

 

  1. Merkel cell carcinoma in Turkey: A multicentric study Fatih Yildiz1, Umut Demirci1, Ahmet Küçükarda2, Mahmut Büyüksimsek3, Teoman Sakalar4, Turkan Ozturk Topcu5, Ferit Aslan1, Gulnihal Tufan1, Ovgu Aydin6, Hande Turna7, Nalan Akgul Babacan8, Tugba Basoglu8, Bediz Kurt9, Birol Yildiz10, Tülay Eren11, Atike Gokcen Demiray12, Ozge Gumusay13, Cagatay Arslan14, Nuriye Özdemir15, Yuksel Urun16, Meltem Baykara17, Nedim Turan18, Mukremin Uysal19, Ahmet Bilici20, Halil Kavgaci5, İrfan Çiçin2, Saadettin Kilickap21, Semra Paydas3, DOI: 10.4103/jcrt.JCRT_950_19.JCRT,Dec2020 (December 2020)

 

  1. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S. J Oncol Pharm Pract. 2020 Oct 13:1078155220963535. doi: 10.1177/1078155220963535. (October 2020)

 

  1. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR1, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortes, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desiree Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, and Priya Rastogi, on behalf of the monarchE Committee Members and InvestigatorsDOI: 10.1200/JCO.20.02514 Journal of Clinical Oncology (September 2020)

 

  1. Evaluating sun protection behaviors and skin self-examination practices among the family members of melanoma patients in Turkey: A cross-sectional survey study. Sarikaya Solak S, Yondem H, Cicin I. Dermatol Ther. 2020 Sep 3:e14268. doi: 10.1111/dth.14268. (September 2020)

 

  1. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey Muhammet Bekir Hacioglu, Osman Kostek, Senem Karabulut, Didem Tastekin, Sema Sezgin Goksu, Celal Alandag, Baran Akagunduz, Irem Bilgetekin, Burcu Caner, Ahmet Bilgehan Sahin, Birol Yildiz, Fatih Kose, Muhammet Ali Kaplan, Ahmet Gulmez, Ender Dogan, Deniz Can Guven, Mustafa Gurbuz, Yakup Ergun, Mustafa Karaagac, Atike Gokcen Demiray, Sema Turker, Teoman Sakalar, Ozlem Ozkul, Tugba Akin Telli, Suleyman Sahin, Saadettin Kilickap, Ahmet Bilici, Bulent Erdogan, Irfan Cicin; JBUON 2020; 25(4): 1897-1903 (August 2020)

 

  1. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Nir Peled, Roni Gillis, Saadettin Kilickap, Patrizia Froesch, Sergei Orlov, Elena Filippova, Umut Demirci, Petros Christopoulos, Irfan Cicin, Fatma Bugdayci Basal, Cengiz Yilmaz, Moiseenko Fedor, Taner Korkmaz, Semra Paydas, Oliver Gautschi Alisan Zirtiloglu, Yesim Eralp, Havva Yesil Cinkir, Ahmet Sezer, Mustafa Erman, Deniz Tural, Hande Turna, Julien Mazieres, Elizabeth Dudnik ,Noemi Reguart, David Ross Camidge, Terry L. Ng, Filiz Çay Şenler İsmail Beypınar, Doğan Yazılıtaş, Ahmet Demirkazık, Aziz Karaoğlu, Kerem Okutur Hasan Şenol Coşkun, Mehmet Ali Nahit Şendur, Abdurrahman Isikdogan, Devrim Cabuk Perran Fulden Yumuk, Ibrahim Yıldız, M. Ali Kaplan, Özgür Özyılkan, İlhan Öztop Omer Fatih Olmez, Kübra Aydin, Adnan Aydıner, Nezih Meydan, Roxana Denisa Grinberg Laila C. Roisman, July 27, 2020. DOI:https://doi.org/10.1016/j.lungcan.2020.07.022

 

  1. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Cid JR, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B. J Thorac Oncol. 2020 Jun 26:S1556-0864(20)30500-1. doi: 10.1016/j.jtho.2020.06.015 (June 2020)

 

  1. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study. Gökyer A, Küçükarda A, Köstek O, Hacıoğlu MB, Uzunoğlu S, Kula O, Kurt N, Üstündağ S, Erdoğan B, Çiçin İ. Int J Clin Oncol. 2020 Jun 26. doi: 10.1007/s10147-020-01729-3. (June 2020)

 

  1. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. Bachet JB, Wyrwicz L, Price T, Cremolini C, Phelip JM, Portales F, Ozet A, Cicin I, Atlan D, Becquart M, Vidot L, Mounedji N, Van Cutsem E, Taieb J, Falcone A. ESMO Open. 2020 Jun;5(3):e000698. doi: 10.1136/esmoopen-2020-000698. (June 2020)

 

  1. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey. Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I. J BUON. 2020 May-Jun;25(3):1337-1347. (May 2020)

 

  1. Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis. Yalcintepe S, Gurkan H, Demir S, Tozkir H, Tezel HA, Atli EI, Atli E, Eker D, Cicin I.Tumori. 2020 May 11:300891620919171. doi: 10.1177/0300891620919171. (May 2020)

 

  1. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. Batur S, Dulger O, Durak S, Yumuk PF, Caglar HB, Bozkurtlar E, Bozkurt S, Tastekin E, Cicin I, Ahiskali R, Rzazade R, Cakir A, Oz B.Bosn J Basic Med Sci. 2019 Dec 28. doi: 10.17305/bjbms.2019.4474. (April 2020)

 

  1. Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer. Kuzucuoglu M, Gokyer A, Kula O, Yekdes AC, Sunal BS, Karamustafaoglu YA, Yoruk Y, Cicin ı. J Coll Physicians Surg Pak. 2020 Feb;30(2):172-176. doi: 10.29271/jcpsp.2020.02.172. (February 2020)

 

  1. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, Laktionov K, Hermes B, Cicin I, Rodríguez-Cid J, Wilson J, Kato T, Ramlau R, Novello S, Reddy S, Kopp HG, Piperdi B, Li X, Burke T, Paz-Ares L. J Clin Oncol. 2019 Nov 21:JCO1901348. doi: 10.1200/JCO.19.01348 (January 2020)

 

  1. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators November 18, 2019DOI:https://doi.org/10.1016/S1470-2045(19)30668-0 (January 2020)

 

  1. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer.Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Bilgin B, Taban H, Kucukarda A, Erturk I, Hızal M, Yıldız B, Yıldırım N, Demirci U, Sendur MA, Utkan G, Kılıckap S, Cicin I, Karadurmus N, Ürün Y.J Oncol Pharm Pract. 2019 Oct 25:1078155219883004. doi: 10.1177/1078155219883004. (January 2020)

 

  1. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102. Bekir Hacioglu M, Kostek O, Kurt N, Kucukarda A, Gokyer A, Ustabasioglu FE, Karatas F, Tuncbilek N, Uzunoglu S, Bilici A, Cicin I, Erdogan B. J BUON. 2019 Sep-Oct;24(5):2198-2204. (September 2019)

 

  1. Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer? Köstek O, Bozkaya Y, Hacıoğlu MB, Yıldırım Özdemir N, Yılmaz E, Demircan NC, Erdoğan B, Uzunoğlu S, Çiçin İ, Zengin N. Arch Iran Med. 2019 May 1;22(5):236-241. (May 2019)

 

  1. Rachel Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, Petr Kavan, Maria Di bartolomeo, evaristo maiello, irfan cicin, Pilar García Alfonso, Ian Chau, Mikhail Fedyanin, Carlos Fernández-Martos, Mikhail Ter-Ovanesov, Marc Peeters, Yoo-Joung Ko, suayib yalcin, Meinolf Karthaus, Jorge Aparicio, Volker Heinemann, Pascaline Picard, Denise Bury, Edward Drea, Alberto SobreroAflibercept plus FOLFIRI for Second-Line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP) , Clinical Colorectal Cancer May 2019DOI: https://doi.org/10.1016/j.clcc.2019.05.003 (May 2019)

 

  1. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases. Boyraz G, Durmus Y, Cicin I, Kuru O, Bostanci E, Comert GK, Sahin H, Ayik H, Ureyen I, Karalok A, Meydanli MM, Salman MC, Ozgul N, Onan A, Simsek T, Yuce K, Turan T. Arch Gynecol Obstet. 2019 Apr 13. doi: 10.1007/s00404-019-05160-6 (April 2019)

 

  1. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Köstek O, Yılmaz E, Hacıoğlu MB, Demircan NC, Gökyer A, Uzunoğlu S, Tunçbilek N, Çiçin İ, Erdoğan B. Cancer Chemother Pharmacol. 2019 Apr;83(4):735-742 (April 2019)

 

  1. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. Köstek O, Demircan NC, Gökyer A, Küçükarda A, Sunal BS, Hacıoğlu MB, Eslame H, Solak S, Yılmaz E, Uzunoğlu S, Tunçbilek N, Çiçin I, Erdoğan B.Clin Transl Oncol. 2019 Mar 28. doi: 10.1007/s12094-019-02079-x (March 2019)

 

  1. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenibGökyer A, Küçükarda A, Köstek O, Hacıoğlu MB, Sunal BS, Demircan NC, Uzunoğlu S, Solak S, İşsever K, Çiçin I, Erdoğan B. . Clin Transl Oncol. 2019 Mar 13. doi: 10.1007/s12094-019-02080-4. (March 2019)

 

  1. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ, Erdoğan B. Cancer Chemother Pharmacol. 2018 Oct 29. doi: 10.1007/s00280-018-3713-6 (November 2018)

 

  1. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Cancer Chemother Pharmacol. 2018 Oct 30. doi: 10.1007/s00280-018-3712-7. (November 2018)

 

  1. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma. Kostek O, Yilmaz E, Bekir Hacıoglu M, Erdogan B, Kodaz H, Turkmen Bekmez E, Hacibekiroglu I, Uzunoglu S, Tuncbilek N, Cicin I. J BUON. 2018 Jul-Aug;23(4):979-984. (September 2018)

 

  1. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. (July 2018)

 

  1. Ozaslan E, Ozkan M, Cicin I, Benekli M, Kocer M, Uysal M, Oksuzoglu B, Isikdogan A, Cubukcu E, Elkiran ET, Dane F, Aliustaoglu M, Sevinc A, Karaoglu A, Ulas A, Gokoz-Dogu G. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA). Clin Appl Thromb Hemost. 2018 Jan 1:1076029617753538. doi: 10.1177/1076029617753538 (February 2018)

 

  1. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators. Lancet. 2017 Nov 18;390(10109):2266-2277. (September 2017)

 

  1. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis. Muhammet Hacioglu B, Kostek O, Erdogan B, Uzunoglu S, Cicin I. J BUON. 2017 May-Jun;22(3):586-591. (May 2017)

 

  1. K-RAS and N-RAS mutations in testicular germ cell tumors.Hacioglu BM, Kodaz H, Erdogan B, Cinkaya A, Tastekin E, Hacibekiroglu I, Turkmen E, Kostek O, Genc E, Uzunoglu S, Cicin I.Bosn J Basic Med Sci. 2017 Apr 20. doi: 10.17305/bjbms.2017. (April 2017)

 

  1. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.İrfan Cicin, Tahsin Özatlı, Esma Türkmen, Türkan Özturk, Melike Özçelik, Devrim Çabuk, Ayşe Gökdurnalı, Özlem Balvan, Yaşar Yıldız, Metin Şeker, Nuriye Özdemir, Burcu Yapar, Özgür Tanrıverdi10, Yusuf Günaydin11, Serkan Menekşe12, Berna Öksüzoğlu, Asude Aksoy13, Bülent Erdogan, M Bekir Hacıoglu, Erkan Arpaci14, Alper Sevinç1, Balkan Med J 2016;33:517-24 (September 2016)

 

  1. KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer. Kodaz H, Taştekin E, Erdoğan B, Hacıbekiroğlu İ, Tozkır H, Gürkan H, Türkmen E, Demirkan B, Uzunoğlu S, Çiçin İ. Balkan Med J. 2016 Jul;33(4):407-10 (September 2016)

 

  1. Unknown primary adenocarcinomas: a single-center experience. Uzunoglu S, Erdogan B, Kodaz H, Cinkaya A, Turkmen E, Hacibekiroglu I, Sari A, Ozen A, Usta U, Cicin I. Bosn J Basic Med Sci. 2016 Jul 25. doi: 10.17305/bjbms.2016.1495. (July 2016)

 

  1. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. Erdogan B, Kodaz H, Karabulut S, Cinkaya A, Tozkir H, Tanriverdi O, Cabuk D, Hacioglu MB, Turkmen E, Hacibekiroglu I, Uzunoglu S, Cicin I. Bosn J Basic Med Sci. 2016 Jul 1. doi: 10.17305/bjbms.2016.1380. (July 2016)

 

  1. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.Turkmen E, Erdogan B, Kodaz H, Hacibekiroglu I, Onal Y, Uzunoglu S, Kilic N, Cicin I.Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):211-5. (June 2016)

 

  1. A rare cause in etiology of left atrial mass: metastatic testicular germ cell tumor, Serhat Huseyin, Volkan Yüksel, Ahmet Okyay, İlhan Hacıbekiroğlu, Ebru Tastekin, Mustafa Yılmaztepe, Gökay Taylan, Suat Canbaz, İrfan Çiçin,Kardiochirurgia i Torakochirurgia Polska 2016; 13 (1): 45-48 (March 2016)

 

  1. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO.Yazıcı O, Özdemir N, Duran AO, Menekşe S, Nahit Şendur MA, Karaca H, Göksel G, Arpacı E, Hacıbekiroğlu İ, Bilgetekin İ, Kaçan T, Özkan M, Aksoy S, Aksoy A, Çokmert S, Uysal M, Elkıran ET, Çiçin İ, Büyükberber S, Zengin N.Future Oncol. 2016 Feb;12(3):343-54. (February 2016)

 

  1. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. Kodaz H, Erdogan B, Hacibekiroglu I, Turkmen E, Tozkir H, Albayrak D, Uzunoglu S, Cicin I. Hepatogastroenterology. 2015 Jun;62(140):876-9. (June 2015)

 

  1. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer. Erdogan B, Turkmen E, Yalta TD, Usta U, Kodaz H, Hacibekiroglu İ, Tanriverdi O, Uzunoglu S, Cicin I. J BUON. 2015 May-Jun;20(3):730-6. (May 2015)

 

  1. Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status. Asian Pac J Cancer Prev. 2015;16(6):2355-9. (April 2015)

 

  1. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer. Tumori 2015; 101(1): 36 - 40 (February 2015)

 

  1. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I. Med Oncol. 2015 Feb;32(2):460. doi: 10.1007/s12032-014-0460-3. (February 2015)

 

  1. Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer. Kodaz H, Erdogan B, Hacibekiroglu I, Turkmen E, Gurkan H, Albayrak D, Tastekin E, Uzunoglu S, Cicin I. Med Oncol. 2015 Jan;32(1):441. doi: 10.1007/s12032-014-0441-6. (January 2015)

 

 

  1. Denosumab - a monoclonal antibody, not a radionuclide. Erdogan B, Cicin I. Asian Pac J Cancer Prev. 2015;16(5):2103.

 

  1. A rarely seen mucoepidermoid carcinoma of the left main bronchus. Kuzucuoglu M, Karamustafaoglu YA, Cicin I, Yoruk Y. J Cancer Res Ther. 2014 Apr-Jun;10(2):384-6. (April 2014)

 

  1. Incidence of contrast-induced nephropathy in hospitalised patients with cancer. Cicin I, Erdogan B, Gulsen E, Uzunoglu S, Sut N, Turkmen E, Kodaz H, Ustundag S. Eur Radiol. 2014 Jan;24(1):184-90. (January 2014)

 

  1. Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs. Erdogan B, Cicin I. Asian Pac J Cancer Prev. 2014;15(4):1503-10.

 

  1. Carnitine or dimethyl sulfoxide, or both, for the treatment of anthracycline extravasation in rats. Uzunoglu S, Cosar R, Cicin I, Ibis K, Demiralay E, Benlier E, Erdogan B, Kandulu H, Ozen A, Altaner S. J Plast Surg Hand Surg. 2013 Oct;47(5):339-43 (October 2013)

 

  1. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma. Erdogan B, Turkmen E, Uzunoglu S, Tanriverdi O, Cicin I. Hepatogastroenterology. 2013 Sep;60(126):1479-83 (September 2013)

 

  1. Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer. Uzunoglu S, Aybatlı A, Kaplan PB, Cicin I, Sut N, Sayın C, Varol F. Med Oncol. 2013 Mar;30(1):447. (March 2013)

 

  1. Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Uzunoglu S, Karagol H, Ozpuyan F, Cosar R, Cicin I, Yurutcaloglu V, Denizli B, Tanriverdi Ö, Sut N, Kocak Z. Med Oncol. 2011 Dec;28 Suppl 1:S690-6. (December 2011)

 

  1. The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study. Saip P, Keskin S, Ozkan M, Kaplan MA, Aydogan F, Gonullu Demirag G, Uzunoglu S, Engin H, Basaran G, Guler N, Uygun K, Demirkan B, Ozdemir F, Cubukcu E, Salepci T, Cicin I. J BUON. 2011 Oct-Dec;16(4):664-71 (October 2011)

 

  1. Breast Conserving Surgery and Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer: Single Center Experience A Sezer, RC Alas, İ Cicin, Z Hoşcoşkun, N Tunçbilek Balkan Medical Journal 28 (2), 138-142 2011

 

  1. Inflammatory myofibroblastic tumor presenting as an abdominal wall mass in an adult patient. Yagci MA, Sezer A, Yeldan E, Coskun I, Usta U, Cicin I, Temizoz O. J Cancer Res Ther. 2010 Apr-Jun;6(2):224-6. (April 2010)

 

  1. A case of malignant melanoma with cardiac and gallbladder metastases detected by FDG PET-CT. Ozülker T, Ozülker F, Cicin I, Ozpaçac T. Clin Nucl Med. 2009 Dec;34(12):948-9. (November 2009)

 

  1. Pleomorphic liposarcoma of the pectoralis major muscle in an elderly man: report of a case and review of literature. Sezer A, Tuncbilek N, Usta U, Cosar-Alas R, Cicin I. J Cancer Res Ther. 2009 Oct-Dec;5(4):315-7 (October 2009)

 

  1. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):210-4. (October 2009)

 

  1. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Sezer A, Usta U, Cicin I. Med Oncol. 2009;26(3):350-7. (September 2009)

 

  1. Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. Cicin I, Karagol H, Usta U, Sezer A, Uzunoglu S, Alas-Cosar R, Yetisyigit T, Uygun K. Med Oncol. 2009;26(3):335-43. (September 2009)

 

  1. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, Yavuz E, Dincer M, Saglam E, Topuz E. J Neurooncol. 2009 Jun;93(2):243-51. (June 2009)

 

  1. Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab. Ozen A, Cicin I, Sezer A, Uzunoglu S, Saynak M, Genchellac H, Karagol H. J Cancer Res Ther. 2009 Apr-Jun;5(2):130-2 (April 2009)

 

  1. Synchronous tonsil, gallbladder, and cardiac metastases without any other visceral metastases of malignant melanoma. Cicin I, Usta U, Sezer A, Canbaz S, Uzunoglu S, Karagol H, Genchellac H, Karasalihoglu AR. Onkologie. 2009 Apr;32(4):197-9 (April 2009)

 

  1. Malignant ovarian germ cell tumors: a single-institution experience. Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C, Tuzlali S, Gorgun O, Topuz E. Am J Clin Oncol. 2009 Apr;32(2):191-6. (April 2009)

 

  1. Extrapulmonary small cell carcinoma localized in lymph nodes: is it a different clinical entity? Cicin I, Usta U, Karagol H, Uzunoglu S, Kocak Z. Acta Oncol. 2009;48(3):354-60. (March 2009)

 

  1. Massive upper gastrointestinal bleeding from pure metastatic choriocarcinoma in patient with mixed germ cell tumor with subclinical intestinal metastasis. Cicin I, Ozyilmaz F, Karagol H, Yalcin F, Uzunoglu S, Kaplan M. Urology. 2009 Feb;73(2):443.e15-7 (February 2009)

 

  1. Factors affecting the prognosis of breast cancer patients with brain metastases. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E. Breast. 2008 Oct;17(5):451-8. (October 2008)

 

  1. Inguinal lymph node as the only evidence of progressive lung cancer. Kocak Z, Saynak M, Oz-Puyan F, Cicin I, Cosar-Alas R, Caloglu M, Altiay G, Uzunoglu S. Rev Port Pneumol. 2008 Sep-Oct;14(5):709-13. (September 2008)

 

  1. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Uygun K, Aksu G, Cicin I, Karagol H, Kocak Z, Fayda M, Binici A, Uzunoglu F. Med Oncol. 2008;25(4):408-14. (September 2008)

 

  1. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Tas F, Duranyildiz D, Soydinc HO, Cicin I, Selam M, Uygun K, Disci R, Yasasever V, Topuz E. Cancer Chemother Pharmacol. 2008 Apr;61(5):721-5. (April 2008)

 

  1. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Gynecol Oncol. 2008 Jan;108(1):136-40. (January 2008)

 

  1. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cicin I, Karagol H, Uzunoglu S, Uygun K, Usta U, Kocak Z, Caloglu M, Saynak M, Tokatli F, Uzal C. Cancer. 2007 Sep 1;110(5):1068-76. (September 2007)

 

  1. Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure. Cicin I, Karagol H, Uzunoglu S, Uygun K. Onkologie. 2007 Feb;30(1-2):65. (February 2007)

 

  1. Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C. Yonsei Med J. 2006 Aug 31;47(4):578-82. (August 2006)

 

  1. Isolated bone metastasis in testicular germ cell tumors: a case report and review of the literature. Uygun K, Karagol H, Kocak Z, Cicin I, Yalcin O, Caloglu M, Simsek O, Harmandar FA. Onkologie. 2006 Mar;29(3):93-5 (March 2006)

 

  1. Unusual metastatic site in a case of carcinoma of the hypopharynx: nasal tip. Kocak Z, Uygun K, Uzal MC, Cicin I, Yalcin O. J Otolaryngol. 2005 Aug;34(4):250-2. (August 2005)

 

  1. Fatal hepatic veno-occlusive disease in an adult patient with Wilms' tumour. Uygun K, Kocak Z, Cicin I, Caloglu M. Clin Oncol (R Coll Radiol). 2003 Sep;15(6):366 (September 2003)

 

  1. Staphylococcal pyomyositis in a patient with non-Hodgkin's lymphoma. Demir M, Cakir B, Vural O, Karakaş HM, Kara M, Ciçin I. Ann Hematol. 2000 May;79(5):279-82 (May 2000)

International Articles

  1. An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. Cicin İ, Oukkal M, Mahfouf H, Mezlini A, Larbaoui B, Ahmed SB, Errihani H, Alsaleh K, Belbaraka R, Yumuk PF, Goktas B, Özgüroğlu M. Eur J Breast Health. 2021 (December 2021)
  1.  
  1. Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn's disease: A case report, Ali Gökyer, Ahmet Küçükarda, Sezin Sayın, Fatma Elif Usturalı Keskin, İrfan Çiçin, https://doi.org/10.1016/j.cpccr.2020.100010 (May 2020)
  1.  
  1. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak A Sezer, İ Cicin, GK Çakmak, SÖ Gürdal, G Başaran, B Oyan, Y Eralp Turk J Surg, 36 (May 2022)
  1.  
  1. Effect of clinical and pathological features of gastrointestinal stromal tumors on overall survival and prognosis: Single center experience, Elif Merev, Irfan Cicin Journal of Oncological Sciences, 2019, https://doi.org/10.1016/j.jons.2019.10.003 (September 2019)
  1.  
  1. Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report .Bekir Muhammet Hacioglu, Osman Kostek, Bulent Erdogan, Hilmi Kodaz, Ilhan Hacibekiroglu, Esma Turkmen, Sernaz Uzunoglu, Irfan Cicin. Journal of Oncological Sciences xxx (2016) 1-2 (December 2016)
  1.  
  1. Endometrial carcinoma and paraneoplastic immune thrombocytopenia. Hilmi Kodaz , Muhammet Bekir Hacioglu,, Cagnur Elpen Kodaz, Ahmet Cinkaya, , Bulent Erdogan Irfan Cicin.Journal of Oncological Science 2 (2016) 25e26 (June 2016)
  1.  
  1. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer. Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Esenkaya A, Onal Y, Uzunoglu S, Cicin I. Mol Clin Oncol. 2015 Sep;3(5):1160-1164. Epub 2015 Jul 1. (September 2015)
  1.  
  1. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Albayrak D, Uzunoglu S, Cicin I. Mol Clin Oncol. 2015 Jan;3(1):179-184. (January 2015)

International Conference Proceedings

  1. 6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. D. Rodriguez Abreu1, M. Reck2, M.A..N. Sendur3, K. Park4, D.H. Lee5, I. Cicin6, P.F. Yumuk7, F.J. Orlandi8, T.A. Leal9, N. Soparattanapaisarn10, A. Langleben11, R. Califano12, B. Medgyasszay13, T. Hsia14, G.A. Otterson15, T. Woods16, E. Jensen16, A. Samkari16, M. Boyer17, Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856. ESMO2022 (September 2022)

 

  1. Three-Year Survival Outcome and Continued Cemiplimab Beyond Progression with the Addition of Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with PD-L1 ≥50%: The EMPOWER-Lung 1 Trial Mustafa Özgüroğlu,1 Saadettin Kilickap,2 Ahmet Sezer,3 Mahmut Gumus,4 , Igor Bondarenko,5 Miranda Gogishvili,6 Marina Nechaeva,7 Michael Schenker,8, Irfan Cicin,9 Ho Gwo Fuang,10 Yaroslav Kulyaba,11 Mikhail Dvorkin,12 Kasimova, Zyuhal,13 Roxana-Ioana Scheusan,14 Manika Kaul,15 Emmanuel Okoye,15 Yuntong Li,15 Xuanyao He,15 Siyu Li,15 Jean-Francois Pouliot,15 Frank Seebach,15, Israel Lowy,15 Giuseppe Gullo,15 Petra Rietschel15 ESMO 2022 (September 2022)

 

  1. 63P. Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer .Shani Paluch-Shimon1 , Patrick Neven2 , Jens Huober3 , Irfan Cicin4 , Matthew P. Goetz 5 , Chikako Shimizu6 , Chiun-Sheng Huang7 , Ran Wei 8 , Sarah C. Nabinger , Tammy Forrester 8 , Nadia Harbeck 9 ESMO Breast 2022 (May 2022)

 

  1. D. Ross Camidge, Fedor Moiseenko, Irfan Cicin, Hidehito Horinouchi, Elena Filippova, Jair Bar, Shun Lu, Pascale Tomasini, Christopher Ocampo, Danielle Sullivan, David Maag, Jonathan W. Goldman. Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT179. (July 2021)

 

  1. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1≥ 50%: Results from EMPOWER-Lung 1 study. Mahmut Gumus, Chieh-I Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Haci M Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidaris, Medha Sasane, Keri Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer.DOI: 10.1200/JCO.2021.39.15_suppl.9078 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9078-9078. ASCO2021 (May 2021)

 

  1. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1)≥ 50%: EMPOWER-Lung 1 subgroup analysis. Mustafa Ozguroglu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Haci M Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Philip R Clingan, Virote Sriuranpong, Naiyer A Rizvi, Jennifer McGinniss, Jean-Francois Pouliot, Sue Lee, Frank A Seebach, Israel Lowy, Giuseppe Gullo, Petra RietschelDOI: 10.1200/JCO.2021.39.15_suppl.9085 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9085-9085. ASCO2021 (May 2021)

 

  1. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Emre Yekeduz, Ismail Erturk, Deniz Tural, Nuri Karadurmus, Serdar Karakaya, Mutlu Hizal, Çagatay Arslan, Hakan Taban, ˘ Ahmet K¨uç¨ukarda, Nihan S¸ent¨urk ¨ Oztas¸, Ozlem Nuray Sever, Gokhan Uçar, Mehmet Ali Nahit Sendur, Umut Demirci, Saadettin Kilickap, Irfan Cicin, Berna Oksuzoglu, Mustafa Ozguroglu, Yuksel Urun, Turkish Oncology Group Kidney Cancer Consortium (TKCC); Feb 11-13, 2021 Virtual ASCO-GU (February 2021)

 

  1. Quality of life and subgroup analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3. Authors: G. Selvaggi1 , Y.-L. Wu 2 Z. Wang3, G. Wu4, E. Poddubskaya5, M. Reck6, T. Mok7, A. Chiappori8, D.H. Lee9 , V.Breder10, S. Orlov11, I. Cicin12, Y. Cheng13, Y. Liu14, Y. Fan15, J. Zhou1 , C. Liang16 , L. Mao1 , L. Horn17 , H.A. Wakelee18 ; 1 WCLC, January 28 - 31, 2021 (January 2021)

 

  1. EMPOWER-Lung 1: Clinical benefits of first-line (1L) cemiplimab monotherapy by PD-L1 expression levels in patients with advanced NSCLC
     Saadettin Kilickap,1 Ahmet Sezer,2 Mahmut Gümüş,3 Igor Bondarenko,4 Mustafa Özgüroğlu,5 Miranda Gogishvili,6 Haci M Turk,7 Irfan Cicin,8 Dmitry Bentsion,9 Oleg Gladkov,10 Philip Clingan,11 Virote Sriuranpong,12 Naiyer Rizvi,13 Siyu Li,14 Sue Lee,14 Tamta Makharadze,15 Semra Paydas,16 Marina Nechaeva,17 Frank Seebach,18 David M Weinreich,18 George D Yancopoulos,18
    Giuseppe Gullo,18 Israel Lowy,18 Petra Rietschel18 January 28 - 31, 2021, WCLC (January 2021)

 

  1. Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 G Selvaggi, HA Wakelee, T Mok, YL Wu, M Reck, A Chiappori, I Cicin, ... Journal of Thoracic Oncology 15 (10), e41-e42 (October 2020)

 

  1. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. A. Sezer1, S. Kilickap2, M. Gümüş3, I. Bondarenko4, M. Özgüroğlu5, M. Gogishvili6, H.M. Turk7, İ. Çiçin8, D. Bentsion9, O. Gladkov10, P. Clingan11, V. Sriuranpong12, N. Rizvi13, S. Li14, S. Lee14, G. Gullo15, I. Lowy15, P. Rietschel15. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. ESMO2020 (September 2020)

 

  1. Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598. Mehmet Nahit Sendur, Martin Reck, Delvys Rodriguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran Fulden Yumuk, Francisco J Orlandi, Ticiana A Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory Alan Otterson, Lu Xu, Thomas A Burke, Ayman Samkari, Michael J Boyer, DOI: 10.1200/JCO.2021.39.15_suppl.9038 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9038-9038. ASCO2021 (May 2020)

 

  1. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access Gul Basaran, Umut Demirci, Fatih Yildiz, Irfan Cicin, Burak Yasin Aktas, Banu Ozturk, Sema Sezgin Goksu, Hasan Senol Coskun, Basak Oyan, Ozlem Sonmez, Yesim Eralp, Erhan Gokmen, Seyda Gunduz, Taner Korkmaz, Mehmet Ali Nahit Sendur, Serkan Keskin, ASCO-2020 Journal of Clinical Oncology 38 (15_suppl), e13055-e13055 (May 2020)

 

  1. P-209 Multicenter real life experience of biological agents in patients with metastatic colorectal cancerU Demirci, I Ertürk, Ç Arslan, A Bilici, D Çevik, I Cicin, F Dane, B Dölek, M Kaplan, N Karadurmuş, F Kose, M Şendur, Y Ürün, S Kılıçkap Annals of Oncology 31, S158 ESMO GI-2020 (May 2020)

 

  1. Sara M. Tolaney, Irfan Cicin, Rafael Betancourt, Arlene Chan, Diego Kaen, Peter A. Kaufman, Suzette Delaloge, Qianying Liu, Sylvaine Cartot-Cotton, Amele Amrate, Vasiliki Pelekanou, Katharine Ellen Cuff;Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies, J Clin Oncol 38: 2020 (suppl; abstr TPS1107) (May 2020)

 

  1. Kilickap, S., et al. "Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?." ANNALS OF ONCOLOGY. Vol. 30. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2019. (November 2019)

 

  1. Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE) R Kanesvaran, B Biswas, P Danchaivijitr, C S Lim, B Karabulut, Y F Wong, H S Coskun, C-H Chang, I Cicin, S Ingles, K Slimane, M Erman Annals of Oncology, Volume 30, Issue Supplement_9, November 2019, mdz446.008, https://doi.org/10.1093/annonc/mdz446.008 (November 2019)

 

  1. Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 L. Paz-Ares1, , D. Vicente2, , A. Tafreshi3 ,, A. Robinson4, H. Soto Parra5, J. Mazie`res6 ,B. Hermes7, I. Cicin8 , B. Medgyasszay9 , B. Beatrix10, J. Rodrıguez Cid11, I. Okamoto12, S. Lee13, R. Ram, ESM0 2019, Barcelona (October 2019)

 

  1. S.L. Chan1, R. Miksad2, I. Cicin3, Y. Chen4, H.J. Klumpen5, S. Kim6, Z.Z. Lin7, J. Youkstetter8, S. Sen8, A. Cheng9, A.B. El-Khoueiry10, T. Meyer11, R.K. Kelley12, G.K. Abou-Alfa1Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC) Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422 (June 2019)

 

  1. Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, Peter C Thuss-Patience, Armando Santoro, Paula Jiménez-Fonseca, Federico Longo, Ozgur Ozyilkan, Irfan Cicin, David Park, Mohamedtaki Abdulaziz Tejani, Aziz Zaanan, Domenico Bilancia, Carles Pericay, Mustafa Ozguroglu, , Lukas Makris, Sandra McGuigan, David H Ilson. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged≥ 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.DOI: 10.1200/JCO.2019.37.15_suppl.4037 Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 4037-4037. (May 2019)

 

  1. Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Irfan Cicin, Luigi Bolondi, Heinz Josef Klümpen, Stephen Lam Chan, Vincenzo Dadduzio, Steven Milwee, Sarita Dubey, Robin Kate Kelley, Anthony B El-Khoueiry.Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial. DOI: 10.1200/JCO.2019.37.15_suppl.4088 Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 4088-4088 (May 2019)

 

  1. 1401P The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. S Kilickap, Ö F Ölmez, I Cicin, U Demirci, O Alan, D Cabuk, T Şakalar, AM Tatlı, F Başol Buğdaycı, Y Eralp, M Uysal, A Demirkazık, B Bilgin, B Yıldız, M Karaağaç, K Okutur, A Sakin. Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy292.023, (October 2018)

 

  1. P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey (ID 14012) (September 2018)

 

  1. Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC. Balazs Halmos,1 Alexander Luft,2 Margarita Majem,3 Rina Hui,4 Romain Corre,5 Mahmut Gümüş,6 Konstantin Laktionov,7 Barbara Hermes,8 Irfan Cicin,9 Andrew G. Robinson,10 Terufumi Kato,11 Ying Cheng,12 Dariusz Kowalski,13 Xiaodong Li,14 Gregory M. Lubiniecki,14 Bilal Piperdi,14 Luis Paz-Ares15, Toronto (September 2018)

 

  1. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.Ghassan K. Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, Yen-Hsun Chen, Joong-Won Park, Jean-Frédéric Blanc, Luigi Bolondi, Heinz Josef Klümpen, Stephen Lam Chan, Vincenzo Dadduzio, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley ASCO 2018 Chicago. (May 2018)

 

  1. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).Lorenza Rimassa, Irfan Cicin, Jean-Frédéric Blanc, Heinz Josef Klümpen, Vittorina Zagonel, Albert Tran, Stefano Chong Hun Kim, Zhong-Zhe Lin, Vincent C Tam, Saswati Hazra, Milan Mangeshkar, Anthony El-Khoueiry, Ann-Lii Cheng, Tim Meyer, Robin Kate Kelley, Ghassan K Abou-Alfa. ASCO 2018, Chicago (May 2018)

 

  1. I. Ciçin, M. Oukkal, H. Mahfouf, A. Mezlini, B. Larbaoui, B.A. Slim, R. Uslu, H. Errihani, K. Alsalef, R. Belbaraka, M. Ozguroglu, B. Goktas. An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting. 11th European Breast Cancer Conference (EBCC-11) , 21-23 Mar 2018 (March 2018)

 

  1. Ghassan K. Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, Joong-Won Park, Jean-Frédéric Blanc, Luigi Bolondi, Heinz Josef Klümpen, Stephen Lam Chan, Vincenzo Dadduzio, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. 2018 Gastrointestinal Cancers Symposium p.207 (January 2018)

 

  1. Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA). | 2017 ASCO Annual Meeting Abstracts abstr e21656) Author(s ): Ersin Ozaslan, Metin Ozkan, Irfan Cicin, Mustafa Benekli, Murat Kocer, Mukremin Uysal, Berna Oksuzoglu, - URL: /199/AbstView_199_188816.html (June 2017)

 

  1. Outcomes of Turkish National Breast Cancer Registry. | 2017 ASCO Annual Meeting Abstracts. Saadettin Kilickap, Mahmut Gumus, Dogan Uncu, Metin Ozkan, Irfan Cicin, Tamer E. Elkiran, Abdurrahman Isikdogan, Aziz Karaoglu, Berna Oksuzoglu URL: /199/AbstView_199_192185.html (June 2017)

 

  1. Characteristics of Turkish colorectal cancer patients and bevacizumab preference. | 2017 ASCO Annual Meeting Abstracts ... 35, 2017 (suppl; abstr e15055) Author(s ): Irfan Cicin, Mahmut Gumus, Dogan Uncu, Metin Ozkan, Saadettin Kilickap, Tamer ... - URL: /199/AbstView_199_192800.html (June 2017)

 

  1. R. Riechelmann1, V. Srimuninnimit2, P. Kavan3, M. Di Bartolomeo4, E. Maiello5, I. Cicin6, H. Kröning7, P. Garcia-Alfonso8, I. Chau9, C. Fernández-Martos10, M. Ter-Ovanesov11, M. Peeters12, P. Picard13, R. Bordonaro14Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP) ESMO2016 (October 2016)

 

  1. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry. By: Kilickap, Saadettin; Altundag, Kadri; Dumanli, Esra; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12656 Published: MAY 20 2015

 

  1. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry. By: Coskun, Ugur; Altundag, Kadri; Aliustaoglu, Mehmet; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12657 Published: MAY 20 2015

 

  1. Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry By: Ciltas, Aydin; Karaca, Mustafa; Uncu, Dogan; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e15056 Published: MAY 20 2015

 

  1. Turkish National Gastric Cancer Registry. By: Buyukberber, Suleyman; Dumanli, Esra; Uncu, Dogan; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12645 Published: MAY 20 2015

 

  1. Turkish National Colon Cancer Registry. By: Benekli, Mustafa; Dumanli, Esra; Kilickap, Saadettin; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12646 Published: MAY 20 2015

 

  1. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry. By: Benekli, Mustafa; Altundag, Kadri; Dumanli, Esra; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12653 Published: MAY 20 2015

 

  1. Turkish National Breast Cancer Registry. By: Altundag, Kadri; Dumanli, Esra; Aliustaoglu, Mehmet; et al. Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015 Sponsor(s): Amer Soc Clin Oncol JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e12654 Published: MAY 20 2015

 

  1. Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA) By: Ozkan, M.; Cicin, I.; Ozaslan, E.; et al. Conference: European Cancer Congress Location: Vienna, AUSTRIA Date: 2015 EUROPEAN JOURNAL OF CANCER Volume: 51 Supplement: 3 Pages: S245-S245 Meeting Abstract: 1619 Published: SEP 2015

 

  1. Uygun, K., I. Cicin, H. Kargol, S. Uzunoglu, Z. Kocak, M. Caloglu ve P. Saip, “The treatment results of patients with extra-pulmoner and pulmoner small cell Cancer,” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 240, Poster sunu 816, Annals of Oncology, 2006.

 

  1. Uygun, K., I. Cicin, H. Karagol, P. Saip ve S. Uzunoglu, “Second line chemotherapy non small cell lung carcinoma: A single-institution experience” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 239, Poster sunu 812, Annals of Oncology, 2006.

 

  1. Uygun, K., H. Karagol, M. Caloglu, I. Cicin, VY. Caloglu, S. Uzunoglu ve P. Saip, “The Comparison of weekly And 3-weekly cisplatin chemotherapy concurrent with radiotherapy in patient with previously untreated inoperable non-metastatic SCCHN,” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 182, Poster sunu 585, Annals of Oncology, 2006.

 

  1. Uygun K., H. Karagöl, İ Çiçin, F Tokatlı, Z Koçak, “Adjuvant chemotherapy in the treatment of curatively resected gastric cancer: as single oncology center experience”, American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, San Francisco, USA, Poster sunu 76, 2006.

 

  1. Cicin I., M. Demir, O.Vural, B. Turgut ve M. Vurkun, “Distribution of haptoglobin subtypes in a Turkish Population from Edirne (East Trakya)-Turkey,” 7th Meeting of the European Hematology Association, Abstract Book, 65, Poster sunu 184, , Florence (2002)

International Books and Book Chapters

  1. Clinical Research at MENA, Ed: Ozdener.Role of Investigator, İrfan Çiçin, Ali Gökyer, p:41-70 Peter, Lang, Wien, 2021 F. ISBN 978-3-631-81113-9 (Print) E-ISBN 978-3-631-86385-5 (E-PDF), E-ISBN 978-3-631-86386-2 (EPUB) (November 2021)

 

  1. Pregnancy and Gastrointestinal Cancers, Chapter 36;Textbook of Gastrointestinal Oncology, Irfan Cicin, Gulay Durmus Altun, Nermin Tuncbilek, Yavuz Atakan Sezer, and Ezgi Cisil Erdogan. ISBN:978-3-030-18888-7, Chapter DOI 10.1007/978-3-030-18890-0_36, 2019 (May 2019)

 

  1. Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides. Breast Disease. 607-617. 2019 Bulent Erdogan, Irfan Cicin. Springer (February 2019)

 

  1. Bone-Targeted Therapy in Advanced Breast Cancer E Esin, I Cicin Breast Cancer, 557-563 (January 2019)

 

  1. Bone-Targeted Therapy in Early Breast Cancer E Esin, I Cicin Breast Cancer, 433-441 (January 2019)

 

  1. Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides,pp 695-709, Chapter 42, Breast Disease, Eds: Aydiner A, İgci A, Soran A, DOI:10.1007/978-3-319-26012-9_42, ISBN:978-3-319-26010-5, Springer (January 2016)

 

 

National Articles

  1. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study.İrfan ÇİÇİNa, Aydın ÇİLTAŞb, Saadettin KILIÇKAPc, Berna ÖKSÜZOĞLUd, Doğan UNCUe, Mehmet ARTAÇf, Havva YEŞİL ÇINKIRg, Abdurrahman IŞIKDOĞANh, Faysal DANEi, Mehmet ALİUSTAOĞLUj, Hacı Mehmet TÜRKk, Emin Tamer ELKIRANl, Erdem ÇUBUKÇUm, Meltem EKENELn, Feyyaz ÖZDEMİRo, Ali GÖKYERa, İlhan ÖZTOPp, Ahmet ALACACIOĞLUr, Hüseyin ÖZTÜRKs, Birkan AVERs, Metin ÖZKANt, J Oncol Sci.2020;6(2):87-95 (August 2020)

 

  1. Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study Ali AYHANa, İrfan ÇİÇİNb, Ali GÖKYERb, Mustafa Erkan SARIc, Ahmet Taner TURANd, Salih TAŞKINe, Kemal GÜNGÖRDÜKf, Özgür AKBAYIRg, Pınar SAİPh, Hanifi ŞAHİNc, Gonca ÇOBANa, Samet TOPUZi, İlker SELÇUKc, Gökhan TULUNAYg, Mehmet Mutlu MEYDANLIc, Doi: 10.37047/jos.2019-73073 -J Oncol Sci. (August 2020)

 

  1. Clinical features of the patient with multiple primary tumors: Single center experience (May 2017)

 

  1. How Many Lines of Chemotherapy Should Be Applied in Metastatic Non-Small Cell Lung Cancer? Sernaz UZUNOĞLU, İrfan ÇİÇİN. Turkiye Klinikleri J Med Oncol-Special Topics 2016;9(4):56-64 (December 2016)

 

  1. Systemic Chemotherapy in Ovarian Germ Cell and Stromal Cancers, Sernaz UZUNOĞLU, İrfan ÇİÇİN, Turkiye Klinikleri J Med Oncol-Special Topics 2016;9(1):41-51 (April 2016)

 

  1. Biyobenzer Ürünlerde Klinik Uygulamada Karşılaşılabilecek Sorunlar.Fatma Ceyda KORUCU, Hakan NAZLI, Gülşah GEDİK, İrfan ÇİÇİN. Marmara Pharmaceutical Journal 20: 44-51, 2016 (January 2016)

 

  1. A case of Guillain-Barre syndrome in a patient with small cell lung cancer treated with chemotherapy Esma TÜRKMEN1, Bülent ERDOĞAN1, İlhan HACIBEKİROĞLU1 Hilmi KODAZ1, Sernaz Uzunoğlu1, Yahya ÇELİK2, İrfan ÇİÇİN1Türk Onkoloji Dergisi 2014;29(3):104-107 (September 2014)

 

  1. Chemotherapy and Targeted Therapy in Castration Resistant Prostate Cancer Sernaz UZUNOĞLUa, İrfan ÇİÇİN Turkiye Klinikleri J Urology-Special Topics 2014;7(4):108-17

 

  1. Hypothermia in Hodgkin’s disease: unexpected state; case report and rewiew of the literature Türk Onkoloji Dergisi 2013;28(1):41-43

 

  1. Treatment of Primary Tumors Relapsed or Refractory Glial and Targeted Therapies S UZUNOĞLU, İ ÇİÇİN Turkiye Klinikleri J Med Oncol-Special Topics 2013;6(1):43-9

 

Read more
© 1993-2025
Medical Park Hospital Groups
Medical Park
Mobile Apps